Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (211-220 of 234) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 24, 2012
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumorsLindsey Oudijk, José Gaal, Esther Korpershoek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2013
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platformAnne-Joy M de Graan, Laure Elens, Marcel Smid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Factors affecting cytochrome P-450 3A activity in cancer patientsSharyn D Baker, Ron H N van Schaik, Laurent P Rivory, et al.
Cancer Research|June 25, 2009
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomasIsabelle Ray-Coquard, Claire Cropet, Martine Van Glabbeke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumorsOtto Soepenberg, Herlinde Dumez, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer CentreMarijke Bontenbal, Geert-Jan Creemers, Hans J Braun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patientsErin R Lepper, Sharyn D Baker, Matt Permenter, et al.
International Journal of Cancer|December 31, 2013
MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressorsCaroline M M Gits, Patricia F van Kuijk, Moniek B E Jonkers, et al.
Pageof 24

Showing results (211-220 of 234) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 24, 2012
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumorsLindsey Oudijk, José Gaal, Esther Korpershoek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2013
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platformAnne-Joy M de Graan, Laure Elens, Marcel Smid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Factors affecting cytochrome P-450 3A activity in cancer patientsSharyn D Baker, Ron H N van Schaik, Laurent P Rivory, et al.
Cancer Research|June 25, 2009
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomasIsabelle Ray-Coquard, Claire Cropet, Martine Van Glabbeke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumorsOtto Soepenberg, Herlinde Dumez, Jaap Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer CentreMarijke Bontenbal, Geert-Jan Creemers, Hans J Braun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patientsErin R Lepper, Sharyn D Baker, Matt Permenter, et al.
International Journal of Cancer|December 31, 2013
MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressorsCaroline M M Gits, Patricia F van Kuijk, Moniek B E Jonkers, et al.
Pageof 24